What is Alterity Therapeutics Ltd (ATHE) stock price today?

Alterity Therapeutics Ltd (ATHE) currently trades at $4.83 per share. The stock has a market capitalization of $88.31M and a P/E ratio of —x.

Is ATHE stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Alterity Therapeutics Ltd has a Smart Value Score of 26/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is 4/9 and Altman Z-Score is 0.32.

What is Alterity Therapeutics Ltd's revenue and earnings?

Alterity Therapeutics Ltd has trailing twelve-month (TTM) revenue of $6.64M with profit margins of -219.90%. Earnings per share (EPS) is $-0.60.

Is Alterity Therapeutics Ltd financially healthy?

Alterity Therapeutics Ltd's Piotroski F-Score is 4/9 (moderate financial health). The Altman Z-Score of 0.32 places it in the distress.

ATHE

Alterity Therapeutics Ltd

NASDAQ: ATHE · HEALTHCARE · BIOTECHNOLOGY

$4.83

-2.52% today

Updated 2026-06-01

Market cap

$88.31M

P/E ratio

—

P/S ratio

13.31x

EPS (TTM)

$-0.60

Dividend yield

—

52W range

$3 – $7

Volume

0.0M

Market cap

$88.31M

P/E ratio

—

P/S ratio

13.31x

EPS (TTM)

$-0.60

Dividend yield

—

52W range

$3 – $7

Volume

0.0M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

6.0

Growth

7.0

Quality

B+

2.0

Profitability

5.0

Valuation

C+

4/9

Piotroski F-Score

Moderate

0.3

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →210 stocks currently score above 75

Price targets

Analyst target

$12.00

+148.45%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

1 Strong Buy0 Buy0 Hold0 Sell0 Strong Sell

Price chart

Stock snapshot

Strengths

+ Revenue growth 74.60% QoQ

+ Debt/equity 0.00x — low leverage

Risks

- Altman Z 0.32 — distress zone

- Thin margins at -219.90%

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$5.12M	$3.92M	$4.02M	$5.44M	$6.64M
Net income	$-12.85M	$-13.81M	$-19.12M	$-12.15M	$-9.44M
EPS	—	—	—	—	$-0.60
Free cash flow	$-12.43M	$-20.04M	$-12.61M	$-11.45M	—
Profit margin	-250.75%	-352.54%	-475.79%	-223.35%	-219.90%

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
ATHE	$88.31M	26	6.0	2.0	5.0	7.0	—	Avoid
LLY	$905.79B	78	10.0	10.0	5.0	6.0	—	Strong Buy
JNJ	$554.67B	59	4.7	9.0	3.3	6.0	-70.64%	Buy
ABBV	$368.38B	63	4.0	8.0	4.0	5.0	-47.73%	Buy
UNH	$364.31B	54	5.3	5.5	4.0	5.5	-19.12%	Buy
AZN	$286.37B	64	6.0	8.5	6.0	5.0	+4.85%	Buy

Smart narrative

Alterity Therapeutics Ltd trades at $4.83. Our Smart Value Score of 26/100 indicates the stock is weak. The company scores 4/9 on the Piotroski F-Score. With an Altman Z-Score of 0.32, it sits in the distress. TTM revenue stands at $6.64M. with profit margins at -219.90%.

Frequently asked questions

What is Alterity Therapeutics Ltd's stock price?

Alterity Therapeutics Ltd (ATHE) trades at $4.83.

Is Alterity Therapeutics Ltd overvalued?

Smart Value Score 26/100 (Grade F, Strong Sell).

What is the price target of Alterity Therapeutics Ltd (ATHE)?

The analyst target price is $12.00, representing +148.4% upside from the current price of $4.83.

What is Alterity Therapeutics Ltd's revenue?

TTM revenue is $6.64M.

Piotroski F-Score?

4/9 — moderate financial health.

Altman Z-Score?

0.32 — distress.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

alteritytherapeutics.com

Quick metrics

P/S ratio13.31x

ROE-46.43%

Beta0.00

50D MA$3.98

200D MA$4.00

Shares out0.02B

Float8.31B

Short ratio—

Avg volume0.0M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

ATHE vs LLY →ATHE vs JNJ →ATHE vs ABBV →Stock screener →